An official website of the United States government
Publication Information
Affiliation
University of Texas Southwestern Medical Center, Dallas, TX 75390-9110, USA.
Authors
Andriole GL Jr, Bautista OM, Clarke HS, Crawford ED, Diokno A, Dixon CM, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Kusek JW, Lepor H, Lieber MM, Lucia MS, McConnell JD, McVary KT, Medical Therapy of Prostatic Symptoms (MTOPS) Research Group, Menon M, Milam DF, Miller GJ, Nyberg LM Jr, Ramsdell JW, Roehrborn CG, Schenkman NS, Slawin KM, Smith JA
Studies
Citation
McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA, Medical Therapy of Prostatic Symptoms (MTOPS) Research Group. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003 Dec 18;349(25):2387-98.Abstract
Benign prostatic hyperplasia is commonly treated with alpha-adrenergic-receptor antagonists (alpha-blockers) or 5alpha-reductase inhibitors. The long-term effect of these drugs, singly or combined, on the risk of clinical progression is unknown.